Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of “Moderate Buy” by Brokerages

Sana Biotechnology, Inc. (NASDAQ:SANA) has been assigned an average recommendation of “Moderate Buy” from the nine research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $9.50.

A number of equities research analysts have commented on SANA shares. Morgan Stanley reiterated an “overweight” rating and set a $12.00 target price on shares of Sana Biotechnology in a report on Friday, March 13th. Rodman & Renshaw started coverage on Sana Biotechnology in a report on Monday, May 11th. They set a “buy” rating and a $16.00 target price on the stock. Weiss Ratings cut Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 1st. HC Wainwright lowered their target price on Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday, March 4th. Finally, Wedbush increased their target price on Sana Biotechnology from $6.00 to $7.00 and gave the company an “outperform” rating in a report on Tuesday, April 14th.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in SANA. Royal Bank of Canada lifted its stake in shares of Sana Biotechnology by 76.8% during the 1st quarter. Royal Bank of Canada now owns 12,285 shares of the company’s stock worth $35,000 after purchasing an additional 5,338 shares during the period. Mercer Global Advisors Inc. ADV purchased a new position in shares of Sana Biotechnology during the 3rd quarter worth $36,000. Lyell Wealth Management LP purchased a new position in shares of Sana Biotechnology during the 3rd quarter worth $37,000. Rockefeller Capital Management L.P. lifted its stake in shares of Sana Biotechnology by 74.3% during the 4th quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock worth $39,000 after purchasing an additional 4,088 shares during the period. Finally, Russell Investments Group Ltd. purchased a new position in shares of Sana Biotechnology during the 3rd quarter worth $39,000. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Stock Performance

Shares of NASDAQ:SANA opened at $2.68 on Friday. The business’s fifty day moving average price is $3.23 and its two-hundred day moving average price is $3.81. The stock has a market cap of $745.82 million, a PE ratio of -2.88 and a beta of 2.14. Sana Biotechnology has a one year low of $2.41 and a one year high of $6.55.

Sana Biotechnology (NASDAQ:SANA) last announced its earnings results on Monday, May 11th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. As a group, equities research analysts predict that Sana Biotechnology will post -0.59 earnings per share for the current fiscal year.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.